Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients
NCT03945162
Recruiting
This is a phase II, open-label, single-arm, multi-center Study conducted in Canada and the United States. Patients with NMIBC CIS (with or without resected papillary disease (Ta, T1)) that are considered Bacillus Calmette-Guerin ("BCG")-Unresponsive or who are intolerant to BCG therapy. BCG-Unresponsive is at least one of the following: At least five of six doses of an initial induction course plus at least two of three doses of maintenance therapy; or, at least five of six doses of an initial i... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/27/2023
Locations: Site 02-012 - University of Chicago, Chicago, Illinois +11 locations
Conditions: Non-Muscle Invasive Bladder Cancer ("NMIBC") Unresponsive/Intolerant to BCG
Register for Updates
KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment
NCT03662126
Recruiting
This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, for the treatment of patients with myelofibrosis (MF) who no longer benefit from treatment with a JAK inhibitor. Inhibition of MDM2 is a novel mechanism of action in MF. This study will be conducted in 2 phases. Phase 2 will determine the KRT-232 recommended dose and dosing schedule; Phase 3 will test KRT-232 vs Best Available Therapy (BAT). Patients in the Phase 3 part of the study will be randomized 2:1 to receive ei... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/26/2023
Locations: The Kirklin Clinic of UAB Hospital, Birmingham, Alabama +190 locations
Conditions: Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Post-Essential Thrombocythemia MF (Post-ET-MF)
Register for Updates
Dietary Counseling or Potassium Supplement to Increase Potassium Intake in Patients With High Blood Pressure
NCT03809884
Recruiting
High blood pressure is the leading cause of cardiovascular disease worldwide. Many medicines are available to lower blood pressures successfully, as well as many non-medical options, such as dietary changes. Some effective dietary changes include decreasing sodium and increasing potassium in the diet. A lot of focus has been on sodium intake yet; potassium intake in the diet remains low amongst adult Canadians. Excellent data exist in the published research reporting that increasing potassium in... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/12/2023
Locations: Ottawa Hospital Research Institute, Ottawa, Ontario
Conditions: Hypertension
Register for Updates
Efficacy of Sodium Thiosulfate and Mannitol in Reducing Ototoxicity in Adult Patients Receiving Cisplatin Chemotherapy
NCT05129748
Recruiting
One common side effect of cisplatin chemotherapy is ototoxicity. The drugs sodium thiosulfate and mannitol may protect against cisplatin-induced hearing loss. Specifically, sodium thiosulfate has been found to protect the cells in the inner ear, and may therefore prevent hearing loss. Mannitol can help sodium thiosulfate enter the inner ear, and ponteially increase the effectiveness of sodium thiosulfate. This study aims to assess the efficacy of sodium thiosulfate and mannitol to reduce the hea... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/12/2023
Locations: Sunnybrook Health Sciences Centre, Toronto, Ontario
Conditions: Ototoxic Hearing Loss
Register for Updates
THERApeutic Outcomes Related to Gut microBIOME in Glioblastoma (GBM) Patients Receiving Chemo-radiation (THERABIOME-GBM)
NCT05326334
Recruiting
This is a pilot or feasibility study to test the study plan and to find out whether enough participants will join a larger study and accept the study procedures. Eligible participants (adults with newly diagnosed glioblastoma multiforme \[GBM\] and had a good tumour resection \[\>= 70% of initial tumour volume\] and plan to receive 6 weeks of chemoradiation followed by up to 6 months of chemotherapy) are asked to donate their own stool samples at 4 different time points during their treatment co... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/12/2023
Locations: The Ottawa Hospital Cancer Centre, Ottawa, Ontario
Conditions: Glioblastoma, IDH-wildtype
Register for Updates
SBRT vs. Conventional Fractionation With HDR Boost for Prostate Cancer
NCT04861415
Recruiting
Random assignment between SBRT and conventionally fractionated boost following HDR brachytherapy for prostate cancer.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
04/11/2023
Locations: Sunnybrook Health Sciences Centre, Toronto, Ontario
Conditions: Prostate Cancer
Register for Updates
The Sunnybrook Type 2 Diabetes Study
NCT04455867
Recruiting
The Sunnybrook Type 2 Diabetes Study (S2DS) is a prospective observational study of people with prediabetes or Type 2 Diabetes Mellitus (T2DM), that aims to understand the aetiologies, manifestations, and clinical consequences of mood and cognitive complications. The study recruits from the services at Sunnybrook Health Sciences Centre and from the neighbouring University Health Network Toronto Rehabilitation Institute Cardiac Rehabilitation Program.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/10/2023
Locations: Sunnybrook Research Institute, Toronto, Ontario
Conditions: Type 2 Diabetes, PreDiabetes
Register for Updates
DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
NCT04920617
Recruiting
This is a Phase 2b, randomized, open label study to assess the safety and efficacy of DPX-Survivac and pembrolizumab, with and without low-dose cyclophosphamide (CPA) in subjects with relapsed or refractory DLBCL.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/05/2023
Locations: Compassionate Cancer Care Medical Group, Fountain Valley, California +49 locations
Conditions: Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma
Register for Updates
Minimally Invasive Surgery of the Gastro-esophageal Junction
NCT01799967
Recruiting
This study will assess short and long term outcomes of individuals undergoing minimally invasive surgery of the gastro-esophageal junction (MISGEJ). Patients will respond to questionnaires on an annual basis evaluating quality of life and functionality following MISGEJ. Hospital charts will also be reviewed on an annual basis to assess patient health outcomes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/28/2023
Locations: Ottawa Hospital Research Institute, Ottawa, Ontario
Conditions: Achalasia, Paraesophageal Hernia, GERD, Epiphrenic Diverticula, Zenker's Diverticulum
Register for Updates
The Parkwood Pacing and Planning™ App
NCT03957343
Recruiting
In efforts to assist people who have had a concussion (mild traumatic brain injury), the Parkwood Pacing and Planning™ app has been developed and tested and will be released to the public. The app uses a point system where users have a daily point maximum assigned based on symptom severity with daily activities (recorded by the users). Users can then schedule their daily activities based on their allowed points. The goal is to help users with symptom self-management by facilitating activity plan... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/23/2023
Locations: Parkwood Institute, London, Ontario
Conditions: Acquired Brain Injury
Register for Updates
Pembrolizumab as Neoadjuvant Therapy for Resectable Stage IA3 to IIA Non-Small Cell Lung Cancer (NSCLC)
NCT04638582
Recruiting
This is a prospective, randomized, single-site, open-label Phase II trial of neoadjuvant pembrolizumab (3 cycles) followed by surgery, versus concomitant neoadjuvant pembrolizumab with platinum doublet chemotherapy (3 cycles) followed by surgery for participants with Stage IA3, IB and IIA non-small-cell lung cancer (NSCLC). Participants will be offered pembrolizumab (6 cycles), and standard of care adjuvant chemotherapy (4 cycles) if applicable.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/20/2023
Locations: McGill University Health Center, Montréal, Quebec
Conditions: Lung Cancer, Nonsmall Cell
Register for Updates
Dexamethasone for Reduction of Post Thoracotomy Pain Syndrome
NCT02112864
Recruiting
Post thoracotomy pain syndrome still affects 50% of patients after a thoracic surgery. Pathogenesis is unclear but there is growing evidence that neuro inflammation may play a significant role. Dexamethasone is a very potent anti-inflammatory drug. The hypothesis of this study is that dexamethasone, given pre operatively, would help reduce the incidence of post thoracotomy pain syndrome 3 months after surgery, by reducing the inflammatory response, in patients undergoing elective thoracic surger... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
03/17/2023
Locations: Maisonneuve-Rosemont Hospital, Montreal, Quebec
Conditions: Chronic Pain, Dexamethasone, Thoracic Surgery, Cytokines
Register for Updates